Sun Pharmaceutical Industries Limited (SUNPHARMA) — Board Meeting Announcement

StockFin.ai Try Free →

📢 Key Event
Board approved FY26 audited results and recommended final dividend of ₹5 per share

🔄 What Changed
Final dividend recommended at ₹5 per share; profit after tax of ₹6,087.0 crores reported

🔮 What's Next
AGM scheduled for 15 June 2026

💡 Investor Takeaway
The dividend signals confidence in financial performance, offering shareholders a meaningful return

Sun Pharmaceutical Industries Limited announced the outcome of its Board meeting held on 22 May 2026, approving audited standalone financial results for FY 2025-26 and Q4 ending 31 March 2026. The company reported total income of **₹49,868.1 crores**, profit before tax of **₹8,490.1 crores**, and profit after tax of **₹6,087.0 crores**. A final dividend of **₹5 per share** was recommended, building on an interim dividend of **₹11 per share**. The auditor issued an unmodified opinion, and the AGM is scheduled for 15 June 2026.

📄 View Original Announcement (PDF)

📊 Stock Analysis — SUNPHARMA ✨ Ask AI About This

About Sun Pharmaceutical Industries Limited (SUNPHARMA)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹4,50,643.09 Cr P/E: 41.3 ROE: 15.1% ROCE: 20.3%

View full SUNPHARMA stock details →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Sun Pharmaceutical Industries Limited (SUNPHARMA) — Board Meeting Announcement

About Sun Pharmaceutical Industries Limited (SUNPHARMA)

Recent Announcements from Sun Pharmaceutical Industries Limited